Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00531622 · ClinicalTrials.gov registry record · Phase 3
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 643
- Enrollment target
NCT00531622 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 643 participants.
The verdict
NCT00531622, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 643 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in patients with major depressive disorder. This study also includes a double-placebo group (saredutant placebo in combination with escitalopram placebo).
Interventions
- DRUG placebo
- DRUG escitalopram
- DRUG saredutant (SR48968)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00531622
The ClinicalTrials.gov registry entry for NCT00531622 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 643 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00531622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00531622 about?
NCT00531622 is a clinical study titled "An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder". The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in patients with major depressive disorder. This study also includes a double-pla...
What is the current status of trial NCT00531622?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 643 participants. The study started on 2007-09. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00531622?
The interventions under investigation include: placebo (DRUG), escitalopram (DRUG), saredutant (SR48968) (DRUG).
Who is sponsoring clinical trial NCT00531622?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.